112 related articles for article (PubMed ID: 1770093)
1. High-performance liquid chromatographic method for direct separation of 5-(p-hydroxyphenyl)-5-phenylhydantoin enantiomers using a chiral tris(4-methylbenzoate) column.
Eto S; Noda H; Noda A
J Chromatogr; 1991 Jul; 568(1):157-63. PubMed ID: 1770093
[TBL] [Abstract][Full Text] [Related]
2. Optical separation of racemic 5-(p-hydroxyphenyl)-5-phenylhydantoin by reversed phase high-performance liquid chromatography using eluents containing beta-cyclodextrin.
Eto S; Noda H; Minemoto M; Noda A; Mizukami Y
Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2742-4. PubMed ID: 1806294
[TBL] [Abstract][Full Text] [Related]
3. Two-dimensional high-performance liquid chromatographic method to assay p-hydroxyphenylphenylhydantoin enantiomers in biological fluids and stereoselectivity of enzyme induction in phenytoin metabolism.
Hsieh CY; Huang JD
J Chromatogr; 1992 Mar; 575(1):109-15. PubMed ID: 1517287
[TBL] [Abstract][Full Text] [Related]
4. [Chiral separation of racemic 5-(p-hydroxyphenyl)-5-phenylhydantoin by RP-HPLC using eluents containing beta-cyclodextrin].
Yao T; Zeng S; Ding H
Se Pu; 1997 Jul; 15(4):316-8. PubMed ID: 15739464
[TBL] [Abstract][Full Text] [Related]
5. A new method for simultaneous quantification of fosphenytoin, phenytoin and its primary metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin in whole blood by ultra-performance liquid chromatography-tandem mass spectrometry.
Suzuki T; Ogawa T; Ueyama J; Iwai M; Kondo F; Seno H
Leg Med (Tokyo); 2018 Sep; 34():64-69. PubMed ID: 30195106
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective determination of p-hydroxyphenyl-phenylhydantoin enantiomers in rat liver microsomal incubates by reversed-phase high-performance liquid chromatography using beta-cyclodextrin as chiral mobile phase additives.
Yao TW; Zeng S
Biomed Chromatogr; 2001 Apr; 15(2):141-4. PubMed ID: 11268054
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective inhibition of diphenylhydantoin metabolism by p-hydroxyphenyl-phenylhydantoin enantiomers in rats.
Huang JD; Hsieh CY
Chirality; 1991; 3(6):454-9. PubMed ID: 1812955
[TBL] [Abstract][Full Text] [Related]
8. Sensitive method for the determination of phenytoin in plasma, and phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in urine by high-performance liquid chromatography.
Maya MT; Farinha AR; Lucas AM; Morais JA
J Pharm Biomed Anal; 1992; 10(10-12):1001-6. PubMed ID: 1298355
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of plasma phenytoin and its primary hydroxylated metabolites in carbon tetrachloride-intoxicated rats by high-performance liquid chromatography.
Tanaka E; Sakamoto N; Inubushi M; Misawa S
J Chromatogr B Biomed Appl; 1995 Nov; 673(1):147-51. PubMed ID: 8925069
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of p-hydroxylated and dihydrodiol metabolites of phenytoin in urine by high-performance liquid chromatography.
Szabo GK; Pylilo RJ; Davoudi H; Browne TR
J Chromatogr; 1990 Dec; 535(1-2):279-85. PubMed ID: 2089057
[TBL] [Abstract][Full Text] [Related]
11. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.
Fritz S; Lindner W; Roots I; Frey BM; Küpfer A
J Pharmacol Exp Ther; 1987 May; 241(2):615-22. PubMed ID: 3572817
[TBL] [Abstract][Full Text] [Related]
12. UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin.
Kim PM; Winn LM; Parman T; Wells PG
J Pharmacol Exp Ther; 1997 Jan; 280(1):200-9. PubMed ID: 8996197
[TBL] [Abstract][Full Text] [Related]
13. Quantification of phenytoin and its metabolites in equine plasma and urine using high-performance liquid chromatography.
Guan F; Uboh CE; Soma LR; Birks EK; Teleis D; Rudy JA; Watson AO; Tsang DS
J Chromatogr B Biomed Sci Appl; 2000 Sep; 746(2):209-18. PubMed ID: 11076073
[TBL] [Abstract][Full Text] [Related]
14. Direct high-performance liquid chromatographic analysis of p-hydroxyphenyl-phenylhydantoin glucuronide, the final metabolite of phenytoin, in human serum and urine.
Vree TB; Steegers-Theunissen RP; Baars AM; Hekster YA
J Chromatogr; 1990 Apr; 526(2):581-9. PubMed ID: 2362000
[No Abstract] [Full Text] [Related]
15. Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study.
Ieiri I; Goto W; Hirata K; Toshitani A; Imayama S; Ohyama Y; Yamada H; Ohtsubo K; Higuchi S
Eur J Clin Pharmacol; 1995; 49(1-2):51-6. PubMed ID: 8751021
[TBL] [Abstract][Full Text] [Related]
16. High-pressure liquid-chromatographic determination of 5-(4-hydroxyphenyl)-5-phenylhydantoin in humanurine.
Kabra PM; Marton LJ
Clin Chem; 1976 Oct; 22(10):1672-4. PubMed ID: 975513
[TBL] [Abstract][Full Text] [Related]
17. Sex differences in rats in the metabolism of phenytoin to 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin.
Billings RE
J Pharmacol Exp Ther; 1983 Jun; 225(3):630-6. PubMed ID: 6864524
[TBL] [Abstract][Full Text] [Related]
18. Liquid-chromatographic method for simultaneous determination of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in plasma and urine.
Sawchuk RJ; Cartier LL
Clin Chem; 1980 Jun; 26(7):835-9. PubMed ID: 7379305
[TBL] [Abstract][Full Text] [Related]
19. Stereoselective glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions.
Nakajima M; Yamanaka H; Fujiwara R; Katoh M; Yokoi T
Drug Metab Dispos; 2007 Sep; 35(9):1679-86. PubMed ID: 17576806
[TBL] [Abstract][Full Text] [Related]
20. Absolute configuration of (+)-5-(o-hydroxyphenyl)-5-phenylhydantoin, the major metabolite of 5,5-diphenylhydantoin in the dog.
Maguire JH; Butler TC; Dudley KH
J Med Chem; 1978 Dec; 21(12):1294-7. PubMed ID: 722736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
